Bianca Muylaert Barrett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bianca Muylaert Barrett has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Cathryn Sibbald
Division of Dermatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, ON, Canada
1 shared publication- Elena Pastukhova
Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada
1 shared publication - Geeta Yadav
FACET Dermatology, University of Toronto, Toronto, ON, Canada
1 shared publication - Milena Music
Family Medicine, University of Toronto, ON, Canada
1 shared publication Perla Lansang
Division of Dermatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, ON, Canada
1 shared publication
Latest Publications
- Open Access
- 28 May 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Retrospective Review of Pediatric Psoriasis and TNF-Inhibitor Induced Psoriasiform Disease in Patients With Skin of Color
Background: Psoriasis affects ~3% of the adult U.S. population, with known differences in prevalence, presentation, and treatment outcomes across racial and ethnic groups. In pediatric populations, disparities in psoriasis recognition may lead to delayed diagnosis and undertreatment, especially in patients with skin of color (SoC). Objectives: To compare clinical presentation and treatment patterns in pediatric patients with psoriasis with and without SoC at a single tertiary-care pediatric center. Methods: We conducted a retrospective, case–control cohort study of patients diagnosed with psoriasis (including TNF-associated psoriasis) before age 18 at SickKids Hospital (January 2008-March 2024). Inclusion criteria were systemic treatment before or after diagnosis of psoriasis and available photo documentation. Patients were stratified by skin phototype based on the Massey-Martin Scale for SoC. Demographics, clinical features, and treatment patterns were compared between SoC and non-SoC groups. Results: Among 115 patients, 42.6% were classified as SoC. Scalp involvement ( P = .008), inflammatory bowel disease ( P = .05), and arthritis were more common in non-SoC patients. SoC patients had a shorter time to diagnosis and were more likely to receive cyclosporine initially and methotrexate overall. Non-SoC patients had higher biologic use throughout care (77.2% vs 63.2%). Topical corticosteroids were the most prescribed treatment across both groups. Conclusions: Pediatric patients with and without SoC showed distinct trends in disease presentation and management. Differences in clinical presentation and medication use highlight the need for increased awareness of psoriasis manifestations in diverse skin types. Prospective studies with standardized assessment tools could help addressing the differences described in this study.
- 28 May 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Open AccessRetrospective Review of Pediatric Psoriasis and TNF-Inhibitor Induced Psoriasiform Disease in Patients With Skin of Color
Background: Psoriasis affects ~3% of the adult U.S. population, with known differences in prevalence, presentation, and treatment outcomes across racial and ethnic groups. In pediatric populations, disparities in psoriasis recognition may lead to delayed diagnosis and undertreatment, especially in patients with skin of color (SoC). Objectives: To compare clinical presentation and treatment patterns in pediatric patients with psoriasis with and without SoC at a single tertiary-care pediatric center. Methods: We conducted a retrospective, case–control cohort study of patients diagnosed with psoriasis (including TNF-associated psoriasis) before age 18 at SickKids Hospital (January 2008-March 2024). Inclusion criteria were systemic treatment before or after diagnosis of psoriasis and available photo documentation. Patients were stratified by skin phototype based on the Massey-Martin Scale for SoC. Demographics, clinical features, and treatment patterns were compared between SoC and non-SoC groups. Results: Among 115 patients, 42.6% were classified as SoC. Scalp involvement ( P = .008), inflammatory bowel disease ( P = .05), and arthritis were more common in non-SoC patients. SoC patients had a shorter time to diagnosis and were more likely to receive cyclosporine initially and methotrexate overall. Non-SoC patients had higher biologic use throughout care (77.2% vs 63.2%). Topical corticosteroids were the most prescribed treatment across both groups. Conclusions: Pediatric patients with and without SoC showed distinct trends in disease presentation and management. Differences in clinical presentation and medication use highlight the need for increased awareness of psoriasis manifestations in diverse skin types. Prospective studies with standardized assessment tools could help addressing the differences described in this study.
- Open Access
- 14 January 2026
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 14
Dual biologic therapy in a patient with severe psoriasis and psoriatic arthritis, using guselkumab and bimekizumab: A case report and review of the literature
Dual biologic therapy is not often used in psoriasis and psoriatic arthritis due to cost and safety concerns, with limited literature supporting its use. We present a case of a 31-year-old man with severe plaque psoriasis and erosive psoriatic arthritis, refractory to multiple therapies. While guselkumab improved skin symptoms, joint inflammation persisted. Given the patient’s reluctance to discontinue guselkumab and his poor response to prior therapies, bimekizumab was added. This combination led to near-complete skin clearance and significant joint improvement within 3 months, with sustained benefits and no adverse effects at 17 months. This case illustrates how targeting multiple points in the interleukin-23/interleukin-17 pathway can improve outcomes in patients unresponsive to monotherapy. Dual biologic therapy may be a viable option for select patients with complex disease, though further research is needed to evaluate its long-term safety and efficacy.
- 14 January 2026
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 14
Open AccessDual biologic therapy in a patient with severe psoriasis and psoriatic arthritis, using guselkumab and bimekizumab: A case report and review of the literature
Dual biologic therapy is not often used in psoriasis and psoriatic arthritis due to cost and safety concerns, with limited literature supporting its use. We present a case of a 31-year-old man with severe plaque psoriasis and erosive psoriatic arthritis, refractory to multiple therapies. While guselkumab improved skin symptoms, joint inflammation persisted. Given the patient’s reluctance to discontinue guselkumab and his poor response to prior therapies, bimekizumab was added. This combination led to near-complete skin clearance and significant joint improvement within 3 months, with sustained benefits and no adverse effects at 17 months. This case illustrates how targeting multiple points in the interleukin-23/interleukin-17 pathway can improve outcomes in patients unresponsive to monotherapy. Dual biologic therapy may be a viable option for select patients with complex disease, though further research is needed to evaluate its long-term safety and efficacy.